drugset
drugset / Trial / NCT05091008

Treatment of Chronic Hepatitis C Infection by Ledipasvir/Sofosbuvir in Naïve Children

NCT05091008 ↗

Phase 2 Completed 50 enrolled Mansoura University Children Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Chronic hepatitis C virus (HCV) infection represents a crucial health problem in children that greatly influence their quality of life. Many efforts have been directed toward the investment of effective drugs with high safety profiles and with oral administration for better compliance. The development of a new direct-acting antiviral (DAA) made it possible to achieve these goals.

Timeline

Start
2018-03-01
Primary completion
2019-08-30
Completion
2020-03-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sofosbuvir Small molecule 90 mg Oral
Comparator Sofosbuvir Small molecule 400 mg Oral

Indications

chronic hepatitis C virus infection